Zibin TIAN, Chunhua BI, Deyu HUANG, Jing JIANG, Yueping JIANG, Cheng BIAN, Hui WANG

Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect

Background/aim: This study aimed to assess expression changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patientswith entecavir treatment and explore the correlation with the curative effect.Materials and methods: A total of 220 HBeAg-positive CHB patients and 207 healthy individuals were included. sPD-1 levels andvirological and biochemical responses were assessed at baseline and at 12, 24, and 48 weeks in CHB patients after antiviral therapy.Results: sPD-1 levels in HBeAg-positive CHB patients before treatment were significantly lower than those of healthy controls. Afterentecavir treatment, sPD-1 levels increased gradually over time. At 48 weeks after entecavir treatment, sPD-1 amounts in the HBeAgseroconversion group were significantly higher than the values of the HBeAg-negative and HBeAg-positive groups. sPD-1 levels inpatients with alanine aminotransferase (ALT) returning to normal were significantly higher than in those with ALT not returning tonormal. sPD-1 levels in treated patients with no HBV-DNA were significantly higher than in those with HBV-DNA remaining positive.sPD-1 was negatively correlated with ALT and HBV-DNA at 12, 24, and 48 weeks after entecavir treatment.Conclusion: sPD-1 may play a certain role in chronic hepatitis B and has a close relationship with the curative effect of entecavir.

PDF

___

Stenejohansen K, Barlinn R. Diagnosis of chronic hepatitis B infection. Tidsskr Norske Laege 2013; 133: 1717-1721.
Liaw Y, Chu C. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
Webster GJ, Reignat S, Brown DA, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini E, Andreone P, Missale G. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-693.
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206-210.
Nielsen C, Ohmlaursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cellular Immunol 2005; 235: 109-116.
Xiao H, Huang B, Yuan Y, Li D, Han L, Liu Y, Gong W, Wu F, Zhang G, Feng Z. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13: 1823-1830.
Wu H, Miao M, Zhang G, Hu Y, Ming Z, Zhang X. Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol Invest 2009; 38: 408-421.
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chinese J Hepatol 2015; 23: 888-905.
Hao AH, Bian C, Xu YH, Liu HY, Wang T, Huang DY. Correlation of T-lymphocyte subsets with serum HBV-DNA loads and HBeAg title among different clinical types of hepatitis B patients. Prog Mod Biomedicine 2012; 23: 4424-4428.
Wherry EJ, Ha S, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27: 670-684.
Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immuno 2008; 45: 963-970.
Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani AC, Brett S, Chokshi S, Naoumov NV. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 759-769.
Xie DY, Chen FJ, Lin BL, Deng H, Chong YT, Zhang XH, Gao ZL. The expressions of PD-1 and PD-L1 and the correlation with the degree of liver damage in HBV chronic infection. Chinese J Exp Clin Infec Dis 2010; 4: 287-293.
Xu L, Liu Y, He X. Expression and purification of soluble human programmed death-1 in Escherichia coli. Cell Mol Immunol 2006; 3: 139-143.
Zhang X, Schwartz JD, Guo X, Bhatia S, Cao E, Lorenz M, Cammer M, Chen L, Zhang Z, Edidin M et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004; 20: 337-347.
Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006; 177: 8844-8850.
He L, Zhang G, He Y, Zhu H, Zhang H, Feng Z. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res 2005; 25: 3309-3313.
Wang D, Zhou D, Du Q, Liang Q, Wang Q, Fang L, Wang G, Fan Q, Liu B, Zhou J et al. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep 2013; 7: 1197-1202.
You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li Y, Lei H, Liu J, Chen H, Tang BZ et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8: 123.